Details
- Close date
- Tuesday, 31 December 2024
- Academic background
- Health Sciences
- Host campus
- Dunedin
- Qualification
- Master's, Honours
- Department
- Pathology (Dunedin)
- Supervisor
- Dr Kunyu Li, Dr Kevin Ly, Professor Antony Braithwaite, Professor Mike Eccles
Overview
Treatment resistance has been reported in all types of anti-cancer therapies and it is one of the major hurdles that limits the outcome of cancer treatment. Many mechanisms of treatment resistance have been identified. However, how exactly these arise remains unclear.
This project aims to understand how immune response might influence genomic alteration in cancer cells and the evolution of the TIME, contributing to the initiation of treatment resistance to immunotherapies, using an animal model of melanoma.
It is suitable for a postgraduate student with substantial knowledge of immunology and/or cancer biology. Students with relevant laboratory experience in primary T cell culturing, mouse handling, tumour monitoring, flow cytometry analysis, and RNA sequencing analysis is preferred.
Depending on the student’s performance and the availability of research funding, this project could be continued for a PhD degree.
Close date
This research opportunity closes on Tuesday 31 December 2024.
Useful information
Similar research opportunities
- A phoenix from the ashes: Do dying cancer cells induce drug-tolerance in lung cancer?
- A role for untranslated p53 mRNA in drug resistance
- Characterisation of YB-1 interactions with the cytoskeleton using live cell imaging
- Comprehensive characterization of uncommon TP53 mutations in cancer
- Defining mechanisms controlling aberrant Fn14 regulation in cancer progression